• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Zealand Pharma A/S

    6/2/22 4:30:46 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email
    6-K 1 tm2217295d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER 

    PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    June 2, 2022

     

     

     

    Commission File Number: 001 - 38178

     

     

     

    Zealand Pharma A/S 

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Sydmarken 11 

    2860 Søborg (Copenhagen)
    Denmark
     

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ¨            Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

     

    Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Zealand Pharma A/S
         
      By: /s/ Matthew Dallas
           
        Name: Matthew Dallas
        Title: Chief Financial Officer

     

    Date: June 2, 2022

     

    2

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
         
    99.1   Company announcement – No. 23/ 2022

     

    3

     

    Get the next $ZEAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    SEC Filings

    View All

    SEC Form 15F-12B filed by Zealand Pharma A/S

    15F-12B - Zealand Pharma A/S (0001674988) (Filer)

    9/30/22 5:24:36 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:20:13 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:16:47 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Leadership Updates

    Live Leadership Updates

    View All

    Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

    Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

    5/19/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

    Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

    4/23/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

    Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

    11/30/23 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zealand Pharma to participate in upcoming investor conferences in September 2025

    Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investor Relations, will host investor meetings on Wednesday, September 3. Cantor Global Healthcare Conference 2025, September 3-5 in New York Adam Steensberg, President and Chief Executive

    8/28/25 11:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

    Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.97

    8/20/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Zealand Pharma

    Berenberg initiated coverage of Zealand Pharma with a rating of Buy

    3/5/24 7:30:01 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Zealand Pharma

    Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

    8/8/23 7:40:54 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma downgraded by Morgan Stanley

    Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

    11/16/22 9:37:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Financials

    Live finance-specific insights

    View All

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

    Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;

    8/7/25 11:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

    6/6/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/14/22 12:27:01 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/3/21 1:13:21 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care